Arcellx (ACLX) Appoints Andrew Galligan and Kristin Myers to Its Board

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market access.

“On the heels of our significant business progress in 2024, we are excited to welcome both Andrew and Kristin to the Arcellx Board of Directors as we continue to accelerate our development pipeline and organizational growth,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “As we take steps toward becoming a commercial-stage company in 2026, their deep knowledge and experience in commercial strategies and operations will complement the robust experience with our existing Board members. Notably, Andrew has been instrumental in building the financial and operational infrastructure to support commercial initiation and growth at multiple public companies. Kristin’s background and executive leadership expertise in the healthcare sector will be invaluable in guiding our market access strategies and patient and physician outreach initiatives.”

Mr. Elghandour added, “As Andrew and Kristin join other members of our distinguished Board of Directors, I would like to thank Derek Yoon for his contributions to our Board. From the earliest stages of our company, his trusted guidance has been instrumental to our growth and success.”

Most recently, Mr. Galligan served as Chief Financial Officer at Nevro Corp., a medical device company in the implantable spinal cord stimulation market. During his 10-year tenure at Nevro, he built the finance and operations group from commercial launch and drove year-over-year revenue growth. Prior to that, he was Vice President, Finance and Chief Financial Officer at Ooma, Inc., where he currently serves as a Board Member. Before that, he served in the same executive capacity at Reliant Technologies, Inc. and helped complete the acquisition of the company by Thermage, Inc. Mr. Galligan’s biotechnology industry executive experience also includes senior financial leadership roles at Metrika Inc. (acquired by Bayer), Corcept Therapeutics Incorporated, and Amira Medical (acquired by Roche). He holds a Business Studies degree from Trinity College, Dublin University, Dublin, Ireland and is a Fellow of the Irish Institute of Chartered Accountants.

“With its lead product candidate, anito-cel, demonstrating meaningful potential in the treatment of relapsed or refractory multiple myeloma, Arcellx is well positioned to address the need for a new treatment option that can make a difference in the lives of patients and their families,” said Mr. Galligan. “As the company prepares for the anticipated commercial launch of anito-cel in 2026, I am pleased to support the Arcellx team in this critical endeavor in my new role as a Board member.”

Ms. Myers brings 20+ years of healthcare experience, including senior leadership roles across the payer, provider and medtech sectors. Currently, she serves as the Chief Operating Officer at Blue Cross Blue Shield Association, leading strategic, operational and technology teams to support the BCBS System. Prior to this, Ms. Myers founded and led Hopscotch Primary Care as the CEO, standing up primary care centers to serve vulnerable patient populations across rural America. Previously, Ms. Myers held several positions of increasing responsibility at Aetna, beginning as Chief of Staff to the CEO and Chairman, and eventually rising to President of the Great Lakes Region. Ms. Myers’ career also included time in venture capital investing in the healthcare and biotech sectors. She holds an MBA from Harvard Business School and a BS in Biomedical Engineering from the University of Wisconsin-Madison.

“The differentiated clinical profile of anito-cel, which is supported by late-stage studies, underscores Arcellx’s potential to change the treatment paradigm in multiple myeloma,” said Ms. Myers. “I look forward to supporting Arcellx’s experienced executive team as it moves closer to the market launch of anito-cel through its partnership with Kite, a Gilead Company.”

You May Also Be Interested In

• Amazon's AWS to acquire DuckLabs, maker of DuckDB database
• Quantum X Labs launches Qatacomb quantum security research initiative
• Cantor Fitzgerald Reiterates Neutral Rating on Zoom Video (ZM) on Strong Q2 Print